Beyond immune checkpoint blockade: what’s next for #melanoma? At #ESMO25, explore: 📌 Why move beyond ICB 📌 #AdoptiveCellTherapy 📌 Treating unresectable stage IV melanoma 📌 Bispecific T-cell engagers 📅 17 Oct | 14:00–15:30 🔗 buff.ly/RaDTAFV

🚀 ESMO is now on Bluesky This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation. Join us for the latest in oncology education and information. #AIOncology #HealthAI #ESMOAI25

📚 Our review on the management of toxicities of cell therapy for solid cancers is now out in print in #ESMO ‘s flagship IO journal ESMO IOTECH. 👉 incl. TILs, TCR-T & CAR-T + associated tx e.g. IL-2 & NMA-LD. 🔗 www.esmoiotech.org/article/S259... @sophiawongyn.bsky.social @fbmh-uom.bsky.social

Just published: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial rdcu.be/d5ptS

Let’s go! 🙌🏼🙌🏼🙌🏼 #CellTherapy #TILTherapy Welcome to 🦋🦋🦋 @drbetofmdphd.bsky.social @sklobuch.bsky.social

Yay 🙌! Our #CellTherapy for solid cancers community is growing here 🦋. Welcome 👋 @drbetofmdphd.bsky.social 🇺🇸 @sklobuch.bsky.social 🇳🇱 @sophiawongyn.bsky.social 🇸🇬 #CancerImmunotherapy